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Abstract
Background: Type 2 diabetes is associated with considerable comorbidity and severe complications, which reduce
quality of life of the patients and require high levels of healthcare. The Diabetes Pearl is a large cohort of patients
diagnosed with type 2 diabetes, covering different geographical areas in the Netherlands. The aim of the study is to
create a research infrastructure that will allow the study of risk factors, including biomarkers and genetic
determinants for severe diabetes complications.
Methods/design: Baseline examinations began November 2009 and will continue through 2012. By the end of
2012, it is expected that 7000 patients with type 2 diabetes will be included in the Diabetes Pearl cohort. To ensure
quality of the data collected, standard operation procedures were developed and used in all 8 recruitment centers.
From all patients who provide informed consent, the following information is collected: personal information,
medication use, physical examination (antropometry, blood pressure, electrocardiography (ECG), retina photographs,
ankle-brachial index, peripheral vibration perception), self-report questionnaire (socio-economic status, lifestyle,
(family) history of disease, and psychosocial well-being), laboratory measurements (glucose, A1c, lipid profile, kidney
function), biobank material (storage of urine and blood samples and isolated DNA). All gathered clinical data and
biobank information is uploaded to a database for storage on a national level. Biobanks are maintained locally at all
recruitment centers.
Discussion: The Diabetes Pearl is large-scale cohort of type 2 diabetes patients in the Netherlands aiming to study
risk factors, including biomarkers and genetic markers, for disease deterioration and the development of severe
diabetes complications. As a result of the well-designed research design and the national coverage, the Diabetes
Pearl data can be of great value to national and international researchers with an interest in diabetes related
research.
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Background
The string of pearls initiative
The String of Pearls Initiative is the product of a unique
partnership between all eight university medical centres
(academic teaching hospitals) in the Netherlands, estab-
lished in 2007 by the NFU (Netherlands Federation of
University Medical Centres). The main aim of the String
of Pearls Initiative is to create a national research infra-
structure, in which biobanks are established in patient
cohorts, combined with a uniform and central clinical
database.
Initially, eight patient cohorts were created, the so-
called “pearls”: cerebrovascular accident, type 2 diabetes
mellitus, hereditary colorectal caner, inflammatory bowel
diseases (Crohn’s disease and ulcerative colitis), leukae-
mia, neurodegenerative diseases, renal failure, rheuma-
toid arthritis and arthrosis. In a standardised way,
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patient materials and patient data are contributed to
each of the patient cohorts in each of the Dutch Univer-
sity Medical Centers [1].
Type 2 diabetes
The International Diabetes Federation estimated that in
2011 approximately 366 million people worldwide had
type 2 diabetes, and they expect this number to have
risen to 552 million in 2030 [2]. An increase in the
prevalence of type 2 diabetes is expected to be a result
of several trends: aging of the population, increased life-
expectancy of patients with type 2 diabetes, earlier de-
tection of type 2 diabetes and increases in the prevalence
of the main risk factors for type 2 diabetes, i.e. adiposity
and lack of physical activity.
Diabetes is associated with considerable comorbidity and
severe complications: cardiovascular disease, nephropathy,
retinopathy and neuropathy. These complications reduce
quality of life of the patient and are a huge burden for na-
tional healthcare. Compared to the general non-diabetic
population, patients with type 2 diabetes have a 2 to 4 fold
higher risk of death from CVD [3]. There is, however, con-
siderable variation in the risk of diabetes complications
within the diabetes population. A large proportion of
patients respond quite well to current therapies. Only a
relatively small proportion (but still a large numbers of
patients due to the high prevalence of diabetes) cannot be
controlled adequately, and have a very high risk of develop-
ing severe complications [4]. At present, no markers are
available to predict the effectiveness of therapies, or to iden-
tify vulnerable patients who are at high risk of diabetes
complications.
Patients with type 2 diabetes in the Netherlands
mainly receive care from their general practitioner (pri-
mary care). In case of complications or inability to
achieve glycemic control, the patient is referred to sec-
ondary care, e.g. specialists in internal medicine, endo-
crinology, ophthalmology and cardiology. In very
complex cases in which high specialist care is needed,
patients are referred to an academic medical center (ter-
tiary care). In 2008, it was estimated that the number of
diabetes related comorbidities was twice as high in sec-
ondary care compared to primary care. Thus, the com-
bination of patients treated in primary, secondary and
tertiary care, is of utmost importance for generating a
representative overview of type 2 diabetes and type 2
diabetes complications in the Netherlands.
Objective of the Diabetes Pearl
The Diabetes Pearls is a large cohort of patients diag-
nosed with type 2 diabetes, covering different geograph-
ical areas in the Netherlands and covering patients
treated in primary, secondary and tertiary care. The aim
of the study is to create a research infrastructure that
will allow the study of (new) risk factors, including bio-
markers and genetic determinants for severe diabetes
complications. The overarching goal is to develop new,
more targeted and effective therapies that will improve
diabetes care and reduce the burden of diabetes.
Methods/Design
Study design
The Diabetes Pearl is an observational cohort study, in
which all eight Dutch academic medical centers partici-
pate. The initial organization of the String of Pearls Ini-
tiative in the Netherland was cofinanced by the Dutch
Government and the eight Dutch academic medical cen-
ters. The continuation is financed by the academic med-
ical centers.
Study population and inclusion criteria
Patients who were diagnosed with type 2 and who
received secondary or tertiary medical care in one of the
6 academic medical centers in Amsterdam, Utrecht, Nij-
megen, Rotterdam, Leiden or Groningen, primary med-
ical care in the area of Hoorn or one of the three types
of care in the region of Maastricht, were eligible for par-
ticipation in the Diabetes Pearl (Figure 1). Patients were
excluded if their ability to understand and write the
Dutch language enabled them to provide written
informed consent.
Ethical considerations, patient information and written
informed consent
All protocols used to create the Diabetes Pearl, and all
generic String of Pearl biobanking and data-procedures
were reviewed as a multi-center study by the ethics com-
mittee of the VU University Medical Center. Ethical
Committies of all seven other academic centers provided
positive advise for participation. To provide patients
with enough time to decide whether or not they wanted
to participate, study information including an informed
consent form was sent by mail prior to their clinic visit.
Upon arrival at the clinic, an oral explanation was pro-
vided and patients who agreed to participate, signed the
informed consent form. Written informed consent
included participation in the study itself as well as separ-
ate consent items covering biobanking, genetic analysis,
and linkageto important national databases like the mu-
nicipality register for mortality follow-up. All partici-
pants received a copy of the signed informed consent.
Baseline data collection of the Diabetes Pearl
Since the start of the String of Pearls Initiative in 2007,
all recruitment centers have worked together to create
the optimal dataset needed to gather baseline data of
patients with type 2 diabetes in the Netherlands. This
minimal dataset was supported by local coordinators of
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the participating clinics and introduced accordingly. In
addition, work instructions were translated into standard
operational procedures (SOPs) to ensure comparability
of all data collected.
Baseline examinations began November 2009 and will
continue through 2012. From all patients who provide
informed consent, the following information was
collected:
1. Demographics and medication use
Hospital information systems at all recruitment
centers were used to collect information on date of
birth and gender. Participants were requested to
bring all their medication on the day of the visit or
lists from pharmacists were used so that medication
use (name, indication for description, dose,
frequency, ATC-code) could be reported accurately.
2. Questionnaire data
All participants received a self-report questionnaire
in which the following items were included:
socioeconomic status of the participants and their
partner, smoking behavior, alcohol consumption
habits and (family) history of diabetes, stroke and
CVD. In addition, a modified version of the Rose
Questionnaire for the diagnosis of ischaemic heart
pain and intermittent claudication [5] and the
EuroQol 5D questionnaire for information on quality
of life [6] were included. In 7 of the 8 recruitment
centers, the questionnaire was extended with the
following items: information on hypoglycaemic
events, the SF-12 questionnaire on quality of life [7],
the PAID Questionnaire on diabetes-related
emotional distress [8], and the DN4 questionnaire on
neuropathic pain [9].
Figure 1 Geographical location of the inclusion centers of the Diabetes Pearl in the Netherlands.
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3. Physical examinations
Weight and height were measured bare foot and
wearing light clothing using a clinical stadiometer
and scale. Waist circumference was measured
between the lower rib margin and the spina iliaca
anterior superior, and the hip circumference over
the maximum of the buttocks. A tape measure was
used in all recruitment centers. Two measurements
of both waist and hip were performed. Final waist
and hip circumference were calculated as the mean
of the two measurements. Blood pressure was
determined three times on the right arm after a
10 minute rest period, using a non-invasive blood
pressure monitor (Omron 7051 T in seven centers,
Colin Press BP 8800p in one center). Final blood
pressure was calculated as the mean of the last 2
measurements.
4. Electrocardiogram
A rest 12-lead electrocardiogram (ECG) was
performed on all participants. ECGs were archived
electronically.
5. Fundus photography
To determine the presence of diabetic retinopathy,
fundus photography of both eyes (with dilated pupils
in case no clear picture could be obtained) was
performed in 7 of the 8 clinics. All fundus
photographs were performed with a non-mydriatic
camera in 45 degrees of at least two fields: one field
centered on the macula and one nasal field with the
optic disc positioned on a disc-diameter from the
temporal edge of the field. This is in accordance with
the EURODIAB protocol [10].
6. Ankle-brachial blood pressure index
As indicator of peripheral arterial disease, we
obtained an ankle-brachial blood pressure index from
all participants in 7 out of the 8 centers. Blood
pressures were measured at the brachial artery of the
left and right arm, and twice at the dorsal pedal
artery and posterior tibial artery of the left and right
ankle. The ankle-brachial index was calculated for
every ankle separately as the highest recorded
pressure on that ankle divided by the highest
pressure in the brachial artery. In 6 centers, the
blood pressures were determined with a Doppler
device and the index was calculated by hand. In one
center, the Omron VP2000 was used, which
determined the blood pressures automatically and
calculated the corresponding ankle-brachial index.
7. Peripheral vibration perception
With the use of a Horwell Neurothesiometer
(Scientific Laboraty Supplies, Nottingham, UK),
peripheral vibration threshold was tested in 7
centers. Vibration thresholds were tested 8 times at
the distal phalanx of the hallux. Mean vibration
threshold was then calculated as the mean of the 6
highest vibration thresholds.
8. Laboratory measurements
Fasting venous blood plasma was used to determine
fasting glucose, total cholesterol, HDL cholesterol,
triglycerides and serum creatinin. A fasting whole
blood sample was used for the determination of
HbA1c level. In addition, a sample of morning urine
was collected and used for the determination of urine
albumin and urine creatinin. All the laboratories
were certified and located on site in the 8 clinics.
9. Biobanking
An important part of the Diabetes Pearl is creating a
national biobank. Therefore, additional samples of
venous blood (serum, EDTA plasma, citrate plasma)
and morning urine (including and excluding anti-
oxidants) were collected for the storage of plasma,
serum and urine. Samples were aliquoted and stored
at -80 degrees. In addition, an EDTA whole blood
sample was collected for DNA extraction. After
isolation (on site in all 8 recruitement centers), a
quality control on the DNA was performed and
DNA was catalogued and stored in -80 degrees
Celsius storage freezers.
Data processing
Since the start of the Diabetes Pearl, much attention is
given to create a solid research infrastructure. As a re-
sult, the Diabetes Pearl consists of a well-designed min-
imal dataset and the use of standardized data collection
procedures across centres. In addition, clinical data,
questionnaire data, laboratory data and biobank infor-
mation are stored on a national level in a highly sophis-
ticated data system. Before the data are uploaded
nationally, several data checks are performed to investi-
gate completeness and correctness of the data. More-
over, participant’s name and address is kept only at the
recruitment center, all uploaded data are pseudono-
mized. Biobank material is also stored anonymous and
standardized storage guidelines have been developed.
Biobank storage is provided local at all recruitement
centers.
Preliminary results
Until February 2012, 4.587 patients were included in the
Diabetes Pearl of whom 2.320 received primary medical
care and 2.267 received secondary or tertiary medical
care. It is to be expected that by the end of 2012, a total
of 7000 patients will be included.
Discussion
The Diabetes Pearl is a national joined initiative of all
University Medical Centers in the Netherlands, aiming
to create a research infrastructure that will allow the
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study of (new) risk factors for disease deterioration and
the development of severe diabetes complications. The
overarching goal is to develop new, more targeted and
effective therapies, which will improve diabetes care and
reduce the burden of diabetes.
The value of the current Diabetes Pearl cohort
Internationally, the use of patient data is increasing in
scientific research. Patient cohort data have the advan-
tage of inclusion of large numbers of patients over wide
coverage. Due to the resemblance with usual care, pa-
tient cohort data can be of great importance in scientific
research and the production of clinical care guidelines
[11]. For example, the General Practitioners Research
Database (GPRD) in the UK, the Swedish National Dia-
betes Register and the China Kandoori Biobank, have
been valuable in various research topics concerning dia-
betes [12-15]. Recently, members of our research group
have used patient data from the Diabetes Care System
West-Friesland to report on the course of retinopathy in
type 2 diabetes patients receiving structured primary
care in the Netherlands [4].
The strengths of the Diabetes Pearl over other (na-
tional and international) patient cohorts include:1) the
national coverage due to the collaboration between the 8
academic medical centers in the Netherlands, 2) the in-
clusion of patients receiving primary care as well as sec-
ondary and tertiary care, providing a representative
overview of type 2 diabetes patients, 3) the combination
of clinical data with the collection of biomaterials, enab-
ling future studies to include determination of specific
biomarkers, including genetic and metabolic markers, in
relation to the occurrence of diabetes complications, 4)
the profound phenotyping, providing essential diabetes-
specific information not available in usual diabetes care
nor in general population biobanking cohorts, 5) the
well-designed research infrastructure, enabling the use
of the Diabetes Pearl biobank and database by other
researchers, and 6) the use of standardizes protocols
throughout all recruitment centers. These specific fea-
tures create a unique research infrastructure, which pro-
mises to be of great value in gaining more insight in the
pathogenesis of type 2 diabetes complications.
The Diabetes Pearl cohort entirely exists of type 2 dia-
betes patients, which is in concordance with our main
aim to study diabetes complications. To study gene-
environment interaction in for example the development
of type 2 diabetes, a representative set of cases and con-
trols is needed. For example, the InterAct Consortium
has established a large-scale case–control study, aiming
to investigate the influence of genetic and lifestyle fac-
tors on the risk of type 2 diabetes. To open the possibil-
ity to include healthy controls in our studies, all
standard operational procedures were harmonized with
large population studies in the Netherlands, like the
Hoorn Study [16] the Maastricht Study and the Life-
Lines cohort.
Follow-up
The ultimate goal of the Diabetes Pearl Research Group
is to increase the knowledge of the occurrence, preven-
tion and effective treatment of diabetes complications.
To reach this goal, we need more insight into the occur-
rence and the determinants and course of diabetes com-
plications, and we need to be able to perform research
on new, targeted treatment strategies. Therefore, we aim
to include at least one follow-up measurement. All base-
line measurements will then be repeated to be able to
investigate changes and prospective associations. In
addition, we have started procedures to initiate a con-
tinuous registration of morbidity and mortality events in
all participants. With the help of the national municipal-
ity register and medical files from local hospitals, accur-
ate information on survival status as well as all
morbidity events will be available. Moreover, initiatives
to link the Diabetes Pearl to a national database with ac-
curate information on medication use, have started. The
resulting longitudinal investigation of type 2 diabetes
patients can be used in for example the identification of
risk factors for diabetes complications, the identification
of individuals at high-risk of complications and the iden-
tification of effective treatment strategies to prevent dia-
betes complications.
Conclusion
In conclusion, this paper described the design of the
Diabetes Pearl, a large-scale, clinically well-defined co-
hort of type 2 diabetes patients in the Netherlands aim-
ing to study risk factors, including biomarkers and
genetic markers, for disease deterioration and the devel-
opment of severe diabetes complications. As a result of
this well-designed study, the national coverage and the
inclusion of patients in all stages of the disease, the Dia-
betes Pearl data can be of great value to national and
international researchers to unravel the pathophysiology
of type 2 diabetes.
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